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Abstract
OBJECTIVE: To investigate the therapeutic effect of
the herbal medication Xiao Pi-II on the symptoms
and gastric motility of patients with functional dys-
epsia (FD).
METHODS: A total of 180 FD patients were divided
randomly and equally into Xiao Pi-II and mosapride
groups. The two groups were treated with Xiao Pi-II
(100 mL, t.d.s., ante cibum) and mosapride (5 mg, t.
d.s., ante cibum) for 2 weeks. Before treatment and
3 days after all medication was stopped, patients re-
sponded to a questionnaire evaluating gastrointes-
tinal symptoms and were assessed with abdominal
three dimensional ultrasonography (3D-US) for gas-
tric motility.
RESULTS: Gastrointestinal symptoms (especially
bloating, post-prandial fullness and eructation)
were improved significantly in FD patients treated
with Xiao Pi-II (P<0.05, P<0.05, and P<0.05), but no
significant difference was found in the mosapride
group (P>0.05). The effective rates in the Xiao Pi-II
and mosapride group were 86.7% and 60.0% , re-
spectively (P<0.05). The gastric liquid emptying
rate (GLER) in the Xiao Pi-II group showed a signifi-
cant increase (P<0.01) after 2 weeks of treatment
but there was no significant change (P>0.05) of
GLER in the mosapride group.
CONCLUSION: Compared with mosapride, Xiao
Pi-II improved symptoms and GLER significantly in
FD patients with delayed gastric emptying.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Functional dyspepsia (FD) is characterized by unex-
plained post-prandial fullness, early satiety and epigas-
tric pain or burning.1 An epidemiological survey in
Western countries showed that the prevalence of FD
ranged from 11.5% to 14.7%.2 FD is a common prob-
lem in outpatients and tends to be a chronic condition.
Some long-term studies demonstrated that symptoms
persisted in >80% of affected patients after 6-7 years of
follow-up,3,4 which reduced patients' quality of life
(QoL)5 and increased the economic burden of medical
care.6
FD is diagnosed if no structural or biochemical expla-
nations for the symptoms can be identified after appro-
priate investigations.1 The etiology and pathophysiolo-
gy of FD remains unclear, but several factors have been
proposed: altered visceral sensitivity and perception;
gastrointestinal motor and secretion dysfunction; infec-
tion by Helicobacter pylori; and psychosocial factors.7-9
Delayed gastric emptying was initially considered to be
the main cause of symptoms in patients with FD9 be-
cause it was reported to occur in a subset of patients
with FD, ranging from 25% to 50% .10 It is assumed
that delayed gastric emptying and consequent pro-
longed antral distension can reduce hunger, increase sa-
298
JTCM |www. journaltcm. com June 15, 2013 |Volume 33 | Issue 3 |
Liu BH et al. / Clinical Study
tiety, and even cause gastric discomfort, all of which
would pose an appreciable barrier to adequate nutri-
tion. Delayed gastric emptying may influence the func-
tion of gastrointestinal secretion, which in turn may
further affect gastrointestinal motility, resulting in alter-
ations in the luminal chemical environment, abnormal
duodenum gastric bile reflux, and FD symptoms.11 Ac-
cordingly, delayed gastric emptying is a focal point of
debate about anorexia caused by dyspepsia, and proki-
netic agents are often administered for its treatment in
Japan.12 Recently, it was reported that post-prandial
fullness was the most severe symptom in patients who
reported aggravation of their symptoms by consuming
a meal.13 Standard pharmacological treatment includes
anti-secretory agents and prokinetics, but these are of-
ten unsatisfactory, leading to the use of largely unprov-
en alternatives.1,14 Dissatisfied patients are likely to
search for alternative medication elsewhere if conven-
tional therapies fail. This is often the case with patients
suffering from functional gastrointestinal disorders
(FGID) because the treatment options have limited ef-
ficacy.15
Based on the Traditional Chinese Medicine (TCM)
theory of "reinforcing spleen Qi", Xiao Pi-II is pre-
pared with nine Chinese herbs: Dangshen (Radix Co-
donopsis), Baizhu (Rhizoma Atractylodis Macrocephalae),
Cangzhu (Rhizoma Atractylodis Lanceae), Fuling (Po-
ria), Banxia (Rhizoma Pinelliae), Sharen (Fructus Amo-
mi), Chenpi (Pericarpium Citri Reticulatae), Zhiqiao
(Fructus Aurantii Submatutus), Gancao (Radix Glycyr-
rhizae), used to regulate gastrointestinal motility and
treat FD. In the present study, we compared Xiao Pi-II
with mosapride for the treatment of FD by assessing
symptomatic improvement, including the rate of emp-
tying of gastric liquids.
MATERIALS ANDMETHODS
Subjects
Patients with FD were recruited from the clinic of the
Gastroenterology Department of the First Affiliated
Hospital of Liaoning Medical University. A total of
180 patients meeting the diagnostic criteria described
below were divided randomly into Xiao Pi-II group
and mosapride group for a single-blind clinical study.
The Xiao Pi-II group comprised 90 patients [47 males;
average age, (42 ± 15) years; range, 21-63 years]. The
mosapride group comprised 90 subjects [49 females;
average age, (43 ± 14) years; range, 23-58 years]. The
study protocol was approved by the Ethics Committee
of the First Affiliated Hospital of Liaoning Medical
University (Jinzhou, China). All participants provided
written informed consent to be involved in the study.
Inclusion criteria
According to the Rome III Diagnostic Criteria for
Functional Gastrointestinal Disorders,16 FD can be di-
agnosed by (a) meal-induced dyspeptic symptoms and
post-prandial distress syndrome (PDS) and (b) epigas-
tric pain. Patients diagnosed with PDS were included
in this study.
The diagnostic criteria of PDS are duration of ≥3
months with onset ≥6 months previously with one or
both of the following symptoms: (a) bothersome
post-prandial fullness occurring after ordinary sized
meals at least several times a week; and (b) early satia-
tion that prevents completion of a regular meal at least
several times per week. The support criteria are: (a) up-
per abdominal bloating, post-prandial nausea or exces-
sive belching can be present; and (b) PSD may coexist
with epigastric pain syndrome (EPS).
All participants underwent endogastroduodenoscopy
(EGD) before enrollment. They were examined by gas-
troenterologists to determine if the EGD observations
were related to current dyspeptic symptoms.
Exclusion criteria
Patients having any one of the following conditions
were excluded: history of peptic ulcers; gastroesophage-
al reflux disease (GERD); mental disorders; aggravat-
ing malignant tumors or other serious consumptive dis-
ease; susceptibility to infection and bleeding; serious
conditions in the cardiovascular, hepatic, renal, gastro-
intestinal or hematological systems. They were also ex-
cluded if they: had contraindications to mosapride;
were unconscious; had previously undergone gastroin-
testinal surgery; were pregnant or lactating.
At the screening phase, patients who were using any an-
tibiotic, proton-pump inhibitor, bismuth salt, prokinet-
ic agent (e.g., itopride) or herbal medication, or who
were participating in any other clinical trial, were ex-
cluded.
Assessment of symptoms
Symptoms were assessed according to the Stanghellini
criteria:17 0=absent; 1=occasionally present but not af-
fecting daily activities; 2=present moderately often,
slightly affecting activities; and 3=present moderately
or more often, affecting activities considerably. The
symptom complex index (SCI) was calculated by divid-
ing the summation of all the scores of the presenting
symptoms by the number of symptoms.
Assessment of efficacy
Efficacy was assessed using the following scale: "notice-
able efficiency" was if the SCI was less than the pre-
treatment value by ≥2; "efficiency" was if the SCI was
less than the pretreatment value by ≥1 but <2; and "in-
efficiency" was if the SCI was less than the pretreat-
ment value by <1.
Dropouts
Dropout cases included those who: had poor compli-
ance; were subjected to severe adverse events; had com-
plications or with special physical changes that meant
that they could not continue the trial; quit the trial by
themselves.
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Treatment
The 90 patients in the Xiao Pi-II group took Xiao
Pi-II: Dangshen (Radix Codonopsis) 15 g, Baizhu (Rhi-
zoma Atractylodis Macrocephalae) 15 g, Cangzhu (Rhi-
zoma Atractylodis Lanceae) 15 g, Fuling (Poria) 15 g,
Banxia (Rhizoma Pinelliae) 15 g, Sharen (Fructus Amo-
mi) 10 g, Chenpi (Pericarpium Citri Reticulatae) 10 g,
Zhiqiao (Fructus Aurantii Submatutus) 10 g, Gancao
(Radix Glycyrrhizae) 10 g. There treated with herbal
medication in the form of a decoction (100 mL three
times a day before meals) for 2 weeks.
The 90 patients in the mosapride group were treated
with mosapride citrate tablets (batch No. 1290C; Dai-
nippon Sumitomo Pharma Co. Ltd., Tokyo, Japan);
5 mg; 3 times a day) for 2 weeks.
Gastric liquid emptying rate (GLER) tested by three
dimensional ultrasonography (3D-US)
Gastric motility was assessed by ultrasonography.18,19
All medication was stopped for 3 days and the patients
were fasted for 12 h before the test. The patients sat in
a chair, leaned slightly backwards, and drank 242 mL
of milk (room temperature; 665.5 kcal; Yili Milk
Group, Neimenggu, China).
The cross-sectional area of the gastric antrum was mea-
sured by ultrasonography. An ultrasound probe was po-
sitioned vertically to permit simultaneous visualization
of the antrum, superior mesenteric artery, and abdomi-
nal aorta. The GLER was estimated by measuring the
change in the antral cross-sectional area between 1 min
and 15 min after ingestion of the test meal.20,21 The
3D-US examiners were unaware of the use of the afore-
mentioned questionnaire. The questions include post-
prandial fullness (the feeling of being uncomfortably
full after a regular-sized meal), and early satiation (in-
ability to finish a regular-sized meal); the frequency of
these symptoms (every day, more than 1 day a week, 1
day a week, 2-3 days a month, 1 day a month, and less
than 1 day a month) during the last 3 months; and
their onset(more than or less than 6 month ago) and se-
verity (very severe, severe, moderate, mild, and very
mild). Persons who had postprandial fullness and/or
early satiation for more than 1 day a week or those
who had epigastric pain on at least 1 day a week with
more than mild severity for more than 6 months were
defined as having PDS. Examinations were conducted
with an external 3D-US diagnosis system (central fre-
quency of the probe: 3.75 Hz; Toshiba, Tokyo, Japan).
The GLER was calculated using the following formula:
GLER=(A1－A15)/A1×100%
A1: antral cross-sectional relaxed area 1 min after inges-
tion; A15: antral cross-sectional relaxed area 15 min af-
ter ingestion
Statistical analyses
All data were analyzed using SPSS ver17.0 (SPSS, Chi-
cago, IL, USA). Data are the mean±standard deviation
( xˉ ± s). The Chi-square test and analysis of variance
were used to explore differences between groups. P<
0.05 was considered significant.
RESULTS
Comparison of symptom scores
Table 1 shows the comparison of the symptom scores
before and after treatment for the two groups. Table 1
demonstrated that Xiao Pi-II could more effectively al-
leviate symptoms of bloating, post-prandial fullness
and eructation (P<0.05, P<0.05, and P<0.05, respec-
tively) than did mosapride. There was no significant
difference in the mosapride group before and after
treatment (P>0.05, Table 1).
Effective rates
Table 2 shows the effective rates for the two groups.
The total effective rate in the Xiao Pi-II group was su-
perior to that of the mosapride group (86.7% vs
60.0% ) and the difference was significant (χ2=5.467,
P=0.033, Table 2).
Group
Xiao Pi-II
Mosapride
n
90
90
Time
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
Epigastic pain
1.62±0.48
1.58±0.67
1.75±0.24
1.83±0.52
Bloating
2.62±0.61
1.16±0.32ab
2.63±0.42
2.34±0.56
Postprandial fullness
2.32±0.57
1.28±0.68ab
2.61±0.43
2.53±0.25
Eructation
2.12±0.69
1.33±0.36ab
2.44±0.77
2.67±0.30
Nausea
1.76±0.46
1.68±0.67
1.47±0.26
1.56±0.52
Notes: aP<0.05, compared with the pre-treatment in the same group; bP<0.05, compared with the Xiao Pi-II group post-treatment.
Table 1 Comparison of the symptom scores before and after treatment for the two groups ( xˉ ±s)
Table 2 Comparison of effective rates
Group
Xiao Pi-II
Mosapride
n
90
90
Curative effect [n (%)]
Markedly effective
36 (40.0)
24 (26.7)
Effective
42 (46.7)
30 (33.3)
Ineffective
12 (13.3)
36 (40.0)
Total effective rate (%)
86.7a
60.0
Note: aP<0.05, compared with the mosapride group.
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Comparison of GLER
Table 3 shows the comparison of the GLER between
the two groups. The GLER in the Xiao Pi-II group was
increased significantly (P<0.01) after 2 weeks of treat-
ment. In contrast, there was no significant change (P>
0.05) in the mosapride group (Table 3).
DISSCUSSION
We found that Xiao Pi-II could increase GLER and im-
prove gastrointestinal symptoms in PDS; Xiao Pi-II
was superior to mosapride. The optimal treatment of
PDS has not been established, but empirical pharmaco-
logical interventions with prokinetic agents have been
shown to be effective in a subgroup of FD patients.22-24
“Prokinetic”refers to a diverse group of medications
that share the common characteristic of accelerating
gastrointestinal motility. Evidence has suggested that
the 5-HT4 (5-hydroxytryptamine 4) receptor-prefer-
ring agonist mosapride is a more promising prokinetic
that stimulates the release of acetylcholine by exciting
the 5-HT4 receptor of the myenteric nerve plexus, and
strengthens the movement of the stomach and duode-
num.25 The gastric emptying time (GET) in the mo-
sapride group was reduced and indicated the obvious
effect of mosapride on shortening the GET. Prokinetic
agents clearly accelerate gastric emptying, but they of-
ten have little effect on (and sometimes can worsen)
symptoms, particularly at higher doses.26-28
Herbal medicines have a long history in the treatment
of dyspeptic condition. A single herb or a combination
of herbs is usually employed. The symptomatology of
PDS is very similar to that of "Pi Man" (a name of a
disease in TCM with bloating as the chief complaint).
Deficiency of the spleen and stomach is the major
cause of PDS. Xiao Pi-II showed significant effects on
improving the symptoms of PDS, mainly owing to its
effect of invigorating the spleen and replenishing Qi.
In terms of TCM theory, the spleen and stomach func-
tion as one. They have vital roles in the metabolism of
digestion and nutrition, and affect the functions of the
immune, hematopoietic and muscular systems. Weak-
ness of spleen and stomach result in hypofunction of
digestion, absorption and metabolism. This leads to a
decrease in internal nutrients and failure of general
functional activities, disturbance of the immune sys-
tem and, eventually, organic degeneration. Taking care
of the spleen and stomach is important for body
strengthening as well as the prevention and treatment
of diseases.29
The main ingredient of Xiao Pi-II, Dangshen (Radix
Codonopsis), has regulatory actions on gastrointestinal
motility, influences basic electrical rhythms in the gas-
trointestinal tract, and reduces the increasing action
of gastric motility and emptying upon stress in rats.30
Fuling (Poria) Cocos possesses inhibitory effects on
mucosal-type mast cells,31 which may (at least in part)
explain the therapeutic effect on functional gastroin-
testinal disorders.32 Cangzhu (Rhizoma Atractylodis
Lanceae), Sharen (Fructus Amomi), and Banxia (Rhi-
zoma Pinelliae) can accelerate delayed gastric empty-
ing in rats.33,34
In conclusion, Xiao Pi-II can improve gastric emptying
and the gastrointestinal symptoms of patients with FD.
The findings lend further evidence to the potential of
Xiao Pi-II as a new option for the treatment of FD.
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